173 related articles for article (PubMed ID: 33622766)
1. Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.
Rust R; Chien C; Scheel M; Brandt AU; Dörr J; Wuerfel J; Klumbies K; Zimmermann H; Lorenz M; Wernecke KD; Bellmann-Strobl J; Paul F
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33622766
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.
Bellmann-Strobl J; Paul F; Wuerfel J; Dörr J; Infante-Duarte C; Heidrich E; Körtgen B; Brandt A; Pfüller C; Radbruch H; Rust R; Siffrin V; Aktas O; Heesen C; Faiss J; Hoffmann F; Lorenz M; Zimmermann B; Groppa S; Wernecke KD; Zipp F
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33762428
[TBL] [Abstract][Full Text] [Related]
3. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
[TBL] [Abstract][Full Text] [Related]
5. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.
Levin J; Maaß S; Schuberth M; Giese A; Oertel WH; Poewe W; Trenkwalder C; Wenning GK; Mansmann U; Südmeyer M; Eggert K; Mollenhauer B; Lipp A; Löhle M; Classen J; Münchau A; Kassubek J; Gandor F; Berg D; Egert-Schwender S; Eberhardt C; Paul F; Bötzel K; Ertl-Wagner B; Huppertz HJ; Ricard I; Höglinger GU;
Lancet Neurol; 2019 Aug; 18(8):724-735. PubMed ID: 31278067
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
9. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
12. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Chataway J; Schuerer N; Alsanousi A; Chan D; MacManus D; Hunter K; Anderson V; Bangham CR; Clegg S; Nielsen C; Fox NC; Wilkie D; Nicholas JM; Calder VL; Greenwood J; Frost C; Nicholas R
Lancet; 2014 Jun; 383(9936):2213-21. PubMed ID: 24655729
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial.
Zhao H; Zhu W; Zhao X; Li X; Zhou Z; Zheng M; Meng X; Kong L; Zhang S; He D; Xing L; Yu J
JAMA Dermatol; 2022 Jul; 158(7):779-786. PubMed ID: 35648426
[TBL] [Abstract][Full Text] [Related]
14. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
Giovannoni G; Knappertz V; Steinerman JR; Tansy AP; Li T; Krieger S; Uccelli A; Uitdehaag BMJ; Montalban X; Hartung HP; Pia Sormani M; Cree BAC; Lublin F; Barkhof F
Neurology; 2020 Aug; 95(8):e1027-e1040. PubMed ID: 32651286
[TBL] [Abstract][Full Text] [Related]
16. Assessing the analgesic efficacy of oral epigallocatechin-3-gallate on epidural catheter analgesia in patients after surgical stabilisation of multiple rib fractures: a prospective double-blind, placebo-controlled clinical trial.
Zhang L; Liu W; You H; Chen Z; Xu L; He H
Pharm Biol; 2020 Dec; 58(1):741-744. PubMed ID: 32749173
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Fox RJ; Coffey CS; Conwit R; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Naismith RT; Ashokkumar A; Barnes J; Ecklund D; Klingner E; Koepp M; Long JD; Natarajan S; Thornell B; Yankey J; Bermel RA; Debbins JP; Huang X; Jagodnik P; Lowe MJ; Nakamura K; Narayanan S; Sakaie KE; Thoomukuntla B; Zhou X; Krieger S; Alvarez E; Apperson M; Bashir K; Cohen BA; Coyle PK; Delgado S; Dewitt LD; Flores A; Giesser BS; Goldman MD; Jubelt B; Lava N; Lynch SG; Moses H; Ontaneda D; Perumal JS; Racke M; Repovic P; Riley CS; Severson C; Shinnar S; Suski V; Weinstock-Guttman B; Yadav V; Zabeti A;
N Engl J Med; 2018 Aug; 379(9):846-855. PubMed ID: 30157388
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study.
Shi DD; Guo JJ; Zhou L; Wang N
J Clin Pharm Ther; 2018 Feb; 43(1):21-25. PubMed ID: 28726273
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
